Search
for
Sort by
Research 30 of 1000+
- Open-label placebos reduce hair cortisol concentrations and psychological distress - a randomized controlled trial
- Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
- Safety and Efficacy of an Oral Nutraceutical Supplement Gummy and Peptide Serum in Promoting Hair Growth: Initial Results of A Randomized Placebo Controlled Trial with an Open Label Extension
- 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
- An Open-label Experience Trial to Evaluate the Effects of a Novel Supplement and Hair Serum Combination on Hair, Skin and Nails in Healthy Women
- An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
- A 6‐Month Open‐Label Clinical Study Evaluating Hair and Skin Parameters After Daily Intake of a Multifactorial Drinkable Nutraceutical in Menopausal and Postmenopausal Women With Female Pattern Hair Loss
- Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
- Evaluation of a Combination of Cystine, B Vitamins and Minerals, in the Management of Diffuse Hair Loss in Women: A Prospective, Open-Label Study
- Comparative efficacy of topical finasteride (0.25%) in combination with minoxidil (5%) against 5% minoxidil or 0.25% finasteride alone in male androgenetic alopecia: A pilot, randomized open-label study
- A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
- Is Oral Finasteride Effective in Reversing Hair Loss in Men with Androgenetic Alopecia
- Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
- Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
- Long-Term Effectiveness of Finasteride for BPH
- Topical Treatments for Scalp Psoriasis
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
- A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor‐Hair Serum for the Prevention of Chemotherapy‐Induced Alopecia
- A 6-Month, Prospective, Multi-arm Study for the Efficacy of Standardized Nutraceuticals to Improve Hair Fiber Thickness and Strength
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- New Drugs: Eculizumab
- An Open-Label Comparative Study on the Effects of Platelet-Rich Plasma Therapy with Hydroquinone 4% Versus Hydroquinone 4% Alone in Melasma
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Evaluation of the efficacy and safety of Narasimham hair oil in promoting hair regrowth and scalp health: A prospective open-label clinical study
- Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
- Pharmacokinetic Interaction of Finasteride With Tamsulosin Hydrochloride: An Open-label, Randomized, 3-period Crossover Study in Healthy Chinese Male Volunteers
- A 6-Month Prospective, Open-Label, Randomized Study Showing Increased Hair Growth Rate in Women Using Multi-Targeting Hair Growth Nutraceuticals
- Efficacy and safety of a botanical shampoo containing <i>Morus alba</i> root extract in Republic of Korea: a single-center, open-label, pilot study in mild to moderate non-scarring alopecia of the scalp
- Ageratum Conyzoides L. Extract Inhibits 5α-Reductase Gene Expression and Prostaglandin D2 Release in Human Hair Dermal Papilla Cells and Improves Symptoms of Hair Loss in Otherwise Healthy Males and Females in an Open Label Pilot Study